Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: A case study

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Takayama, Tatsuya ^a   Furuse, Hiroshi ^a   Kai, Fumitake ^a   Sugiyama, Takayuki ^a   Ozono, Seiichiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Long term; Renal cell carcinoma; Temsirolimus

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; RAPAMYCIN;

ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; HEART TAMPONADE; HUMAN; HYPOXIA; INTERSTITIAL PNEUMONIA; KIDNEY METASTASIS; LOW DRUG DOSE; LUNG EMPHYSEMA; LUNG LESION; LUNG METASTASIS; MALAISE; MALE; NAIL DISEASE; NEPHRECTOMY; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RASH; SIDE EFFECT; THORAX RADIOGRAPHY; THROMBECTOMY; THROMBOCYTE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIDEO ASSISTED THORACOSCOPIC SURGERY; WEIGHT REDUCTION; KIDNEY CARCINOMA; KIDNEY TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC);

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MALE; SIROLIMUS;

EID: 84875499907     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0563-2     Document Type: Article

References (11)

1. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res. 2008;14:1286-90.
2. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-18.
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. Temsirolimus, interferon-alpha or both for advanced renal cell carcinoma. N Engl J Med. 2007;356:2271-81.
4. Sun Y, Rha S, Lee SH, Guo J, Ueda T, Qin S, Naito S, Cincotta M, Tokushige K, Akaza H. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 2012;42:836-44.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
6. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144-50.
7. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-8.
8. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619-28.
9. Martin B, Edeline J, Patard JJ, Oger E, Jouan F, Boulanger G, Zerrouki S, Vigneau C, Rioux-Leclercq N. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. J Cancer Res Clin Oncol. 2012;138:907-16.
10. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012;14:1511-8.
11. Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Biochem Pharmacol. 2012;83:1146-58.